Full-Time

Director of Health Economics and Field Reimbursement

Shockwave

Posted on 9/30/2025

Deadline 10/13/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$160k - $317.4k/yr

New Hope, PA, USA + 8 more

More locations: Horsham, PA, USA | Irvine, CA, USA | Dallas, TX, USA | Santa Clara, CA, USA | Edison, NJ, USA | Bridgewater, MA, USA | New York, NY, USA | Palm Beach Gardens, FL, USA

Remote

This is a field-based remote role available in all states/cities within the United States. Specific cities listed are examples only and do not limit applications.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Minimum 10+ years of professional experience, with 7+ years of work experience in implantable medical device market access/reimbursement industry, with specific responsibility/experience in obtaining coding, coverage and payment for new therapies in the US healthcare system.
  • BS/BA degree required. Advanced degree (e.g., MS, MPH, or PhD) in health policy, health services research, public health, economics, or related discipline preferred.
  • Previous experience in implantable medical device reimbursement, health economics and/or outcomes research and experience in commercialization of disruptive medical devices
  • Demonstrated knowledge of U.S. healthcare systems including expertise in reimbursement pathway development and technology assessment processes.
  • Working acumen of healthcare systems and market access in major global markets.
  • Experience working with/in CPT, HCPCS, RUC and CMS outpatient/inpatient preferred.
  • Ability to effectively work and communicate across cultures and a breadth of functions/levels.
  • Analytical competencies to structure complex issues, synthesize key points, communicate and present in an easily understandable manner.
  • Strong organization and planning skills.
  • Self-motivated with excellent time management skills.
  • Ability to work effectively with minimum supervision essential.
  • Ability to grow with the organization and demonstrate a willingness to assume additional responsibilities over time.
  • Competence and credibility to build relationships of trust with physicians and associated professional staff at clinical centers.
  • Strong communication, interpersonal and problem-solving skills.
  • Ability to manage and deliver on multiple concurrent projects, including management of multiple consultants.
  • Ability to interpret and integrate business strategies into actionable, value-added reimbursement and outcomes planning initiatives.
  • Outstanding communication and interpersonal skills including developing relationships at all levels in an organization and among influential external parties.
  • Enthusiastic, positive, and professional team player.
  • Travel up to 40%.
Responsibilities
  • Lead and support access and reimbursement initiatives for current and future products in the US.
  • Advocate with KOLs, physician societies, and AMA on coding and RUC evaluation.
  • Develop and execute a national field reimbursement strategy aligned with corporate objectives and payer dynamics.
  • Serve as a senior leader within the Market Access team, contributing to pricing, access, coverage, and advocacy strategies.
  • Collaborate closely with Sales Leadership to ensure alignment between field reimbursement and sales activities.
  • Serve as the subject matter expert in procedural and diagnostic coding (ICD-10, CPT, HCPCS) relevant to Shockwave Medical cardiovascular devices.
  • Provide strategic guidance on billing procedures, revenue cycle workflows, and coverage policies.
  • Educate field teams and provider stakeholders on proper documentation and submission processes to ensure compliant reimbursement.
  • Monitor emerging trends and updates in coding and payment policy at the federal and commercial payer levels.
  • Establish strong partnerships with internal cross-functional leaders (e.g., Sales, Marketing, Medical Affairs, Legal, Compliance).
  • Serve as a key point of escalation for complex access challenges or escalated provider/payer issues.
  • Analyze field feedback to drive continuous improvement in strategy, tools, and training.
  • Use denials data to drive regional approaches and address regional hotspots.
  • Deliver regular performance updates to senior leadership and recommend corrective actions.
  • Hire, train, and lead a high-performing team of FRMs across the U.S.
  • Set performance goals, establish KPIs, and oversee execution of territory-level access initiatives.
  • Provide coaching, mentorship, and development planning for team members.
  • Partner closely with sales, marketing, clinical, and other key functions to ensure alignment on field reimbursement strategy and execution.
  • Manage multiple global consultants and projects to support strategic access initiatives.
  • Create and manage educational/promotional materials for reimbursement.
  • Train the field commercial team.
  • Understand and anticipate global data requirements.
  • Support data development and value analyses relevant to diverse payer systems.
  • Monitor health policy and regulatory developments affecting reimbursement.
  • Collaborate with internal/external stakeholders on access policies.
  • Engage proactively with the U.S. CMS rule-making process.
  • Collaborate on activities related to Medicare, State Medicaid, and U.S. Military Health initiatives.
  • Develop and implement strategies to secure optimal reimbursement, focusing on Medicare, Medicaid, and other payer groups.
  • Contribute to the development and writing of clinical and economic outcomes research to support access strategies.
  • Create and manage health economic models to demonstrate the value proposition of medical devices.
  • Build relationships with key stakeholders including government, physicians, hospitals, and payers.
  • Lead awareness campaigns.
  • Collaborate with cross-functional teams on economic value messaging to support product adoption.
  • Provide functional input to portfolio development and pricing strategies.
  • Ensure market access needs are addressed.
  • Participate in internal teams and present strategies aligned with business plans.
  • Manage reimbursement support for key internal/external stakeholders.
  • Facilitate prior authorization and appeal processes.
  • Manage field team services and ensure customers receive top-tier support.
  • Analyze healthcare policy to ensure the environment supports product launches and pipeline technologies.
  • Foster strong collaboration across departments.
  • Stay up to date on clinical trials to enhance health economic value messaging.
  • Perform additional duties as assigned by the Vice-President of Market Access.
Desired Qualifications
  • Experience working with/in CPT, HCPCS, RUC and CMS outpatient/inpatient preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE